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The number of cases of head and neck (H&N) cancer diagnosed in the UK has been
increasing in recent years. These cancers often require complex surgical treat-
ments and extensive rehabilitation. OBJECTIVES: To use data from the Hospital
Episode Statistics (HES) database to estimate the costs incurred by English NHS
hospitals due to treatment of H&N cancers, with a particular focus on oral cavity,
oropharyngeal and laryngeal cancers. METHODS: Inpatient admissions for H&N
cancer between the years 2006/07 to 2010/11 were retrospectively analysed. Data
was obtained from HES, a database covering English hospital activity, with inpa-
tient episodes aggregated into spells of care associated with a specific Healthcare
Resource Group (HRG). The HRGs were linked to costs from the UK National Tariff
in order to calculate the average annual and per patient payments for inpatient
treatment of H&N cancer, as per the NHS Payment by Results framework. Where
necessary, costs were supplemented by expert opinion and other published cost
estimates. RESULTS: Payments to NHS hospitals in England for inpatient stays due
to H&N cancer are estimated to cost on average £57.1 million per year. The main
driver of costs are the disproportionately high number of male cases, the costs of
which are £12,517,235, £13,327,351 and £16,185,743 for oral cavity, oropharyngeal
and laryngeal cancer, respectively. This translates to respective inpatient costs per
male of £5,354, £6,926, and £6,693. Despite similar costs per female inpatient, the
average annual payments for inpatient care were approximately £7,579,905,
£4,337,947 and £3,166,535, for oral cavity, oropharyngeal and laryngeal cancers.
CONCLUSIONS: Based on inpatient treatment alone, H&N cancers place a signifi-
cant economic burden on English NHS hospitals. This, however, is far less than the
total burden of treatment as a large proportion is delivered in the outpatient set-
ting. Further research is currently underway to quantify this total burden.
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OBJECTIVES: To estimate the costs associated with prostate cancer (PC) for Russia
in 2009. METHODS: We used the standard cost of illness (COI) method, relying on
the prevalence approach and adopting the viewpoint of the payers (national and
regional governments). We calculated direct medical costs (hospital and outpatient
services and drugs provided in outpatient care), non-medical costs (monetary pay-
ments in social benefits) and indirect costs (projected productivity loss due to
sickness and disability) associated with the PC in Russia in 2009. The data for
analysis was obtained from the national statistics, regional cancer and prescription
registries, expert panel interviews and literature. The costs were calculated for the
total population of PC patients in Russia. To calculate direct medical costs, we used
national reimbursement rates per unit of care (1 hospital day or 1 visit to an out-
patient oncology clinic) and regional data on prostate cancer drug costs. To access
non-medical costs, we used data on social benefits expenditures. Indirect costs
were estimated with friction costs method. RESULTS: The total costs of prostate
cancer in Russia in 2009 was 3,674 billion RUR (€89,98 mln), or 33 270 RUR (€814) as
average cost per patient per year. More than half of total cost (65,4%) occur in
patients during the 1st year after diagnosis. The direct medical costs accounted for
73,1% of total spending, direct non-medical costs – for 19,7%, and indirect costs – for
7,17%. Direct medical costs represented 86,6% of total spending in PC patients
within the 1st years after the diagnosis; during the subsequent years after the
diagnosis this number reduces to 47,8%. CONCLUSIONS: Our analysis demon-
strates that the most significant part of spending in prostate cancer overall is
related to direct medical costs during the 1st year after the diagnosis.
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OBJECTIVES:With current and increasing pressures to limit expenditure for health
care provision in many countries, a better understanding of the cost burden of
colorectal cancer (CRC), as well as specific determinants and drivers of expenditure
is needed. Cost estimates for individual patients vary widely, according to the data
source. Cost-of-illness (COI) studies are a useful tool to analyse and critically eval-
uate cost aspects of colorectal cancer. METHODS: A systematic review was con-
ducted from 2002 to 2012 to identify COI studies related to colorectal cancer,
searching the Medline, PubMed, Science Direct, Cochrane Library and the York CRD
databases. The search was in line with PRISMA guidelines. Studies that used prev-
alence-based approaches were grouped separately from those studies reporting
incidence-based estimates. RESULTS: Of the total of 11 studies, 6 studies reported
prevalence-based estimates, and 5 studies focused on incidence-based data. In the
studies included in the review, long term costs for colorectal cancer of up to 50,175$
per patient (2008 values) have been estimated. Most studies in the review have
shown that the initial and terminal phases of colorectal cancer care are the most
expensive, with the least costly phase for continuing treatment. However, one
study also highlighted that stage I CRC disease was the least costly, with stage III
the most costly of all four stages, due to the high cost impact of biological agents.
CONCLUSIONS: COI studies in colorectal cancer can identify specific components
and areas of care that are especially costly, thereby establishing attention for more
cost-effective approaches, especially relevant to the increased use of biological
agents in the field of personalized medicine. Future cost-of-illness studies would
greatly benefit from common approaches to methodology, concerning study de-
sign, description and cost component data. COI studies are an important tool for
HTA and especially health economic evaluations of personalized medicine.
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OBJECTIVES: Understand treatment patterns and quantify resource utilization of
HR HER2– ABC, with the overall aim of comparing costs and disease burden as
patients progress from hormonal therapy (HT) to chemotherapy (CT). METHODS:
Chart audit in France, Germany, The Netherlands, Belgium, and Sweden of 375
living and deceased postmenopausal female patients diagnosed with estrogen-
and/or progesterone-receptor–positive HER2– ABC in the past 4 years. Patients
were required to have progressed on 1 line of prior HT in the adjuvant or ad-
vanced setting and to have completed1 line of CT treatment (2 full cycles) in the
ABC setting. The chart audit was completed online using a standardized form
developed with the assistance of European academic physicians, pharmacy direc-
tors, and hospital administrators. Participation was sought from 12-21 oncologists
per country, except in Germany (11 oncologists and 10 gynecologists to reflect local
clinical practice). Data collection complied with European and country market re-
search regulations. RESULTS: Preliminary analyses included 265 charts (80% of
patients between 40 and 69 years of age) with one-third having de novo ABC, one-
third progressing during or within 1 year of adjuvant therapy, and one-third being
late progressors. In the first-line ABC setting, 57% received HT (nearly 90% pro-
gressed to CT in second-line), 43% CT, and 15% also targeted therapy (mostly bev-
acizumab). The switch from HT to CT was associated with a marked increase in
resource utilization and associated costs. Besides drug acquisition and administra-
tion costs, the main CT cost drivers were management for major CT side effects
(low blood cell counts, febrile neutropenia, neurotoxicity, mucositis) and side-ef-
fect–related hospitalization events (14% and 7% of all hospitalization events in
first- and second-line CT, respectively). CONCLUSIONS: Our results highlight the
increased costs and disease burden for postmenopausal HR HER2– ABC patients
treated with CT versus HT in EU countries.
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OBJECTIVES:Bevacizumab, a humanized monoclonal IgG antibody against the vas-
cular endothelial growth factor (VEGF), is reimbursed in the Czech Republic in
combination with chemotherapy for the first-line treatment of patients with met-
astatic colorectal cancer (mCRC). However, its high cost is a potentially limiting
factor. METHODS: The cost and effectiveness of bevacizumab in the real clinical
practice was retrospectively evaluated in the National comprehensive cancer cen-
ter from the perspective of health care payer. Cost data (examination, medication,
hospitalization) were collected since the initiation of bevacizumab treatment to
any tumor response (RECIST criteria - Complete Response (CR), Partial Response
(PR), Stable Disease (SD), Progressive Disease (PD)) and/or to death. Minimal fol-
low-up for all patients was 12 months. Costs were valued in CZK and converted to
EUR (€1CZK 25.78). RESULTS:A total of 218 patients with mCRC were treated with
bevacizumab in the first line treatment (132 men (60.6%); mean age 58.3 years)
between 11/2005-12/2010. The most frequent chemotherapeutic regimens were:
XELOX (55%), FOLFOX (26%), and FOLFIRI (4%). The treatment was mostly discon-
tinued due to PD (59% patients); further due to SD, PR or CR (total 8.3% patients),
adverse events (7.8% patients), surgery (5.5% patients). During our follow-up period
PD was recorded in 89% patients; 66% patients died. The mean cost per progres-
sion-free survival (median 9.1 months) was EUR 38,870.3 (CZK 1,002,076.3); the
mean cost to response PR, CR or SD was EUR 42,894.6 (CZK 1,105,823.1) after median
9.8 months of treatment. The median overall survival was 16.9 months and the
mean cost since initiation of treatment to death was EUR 50,791.3 (CZK 1,309,400.8).
CONCLUSIONS: The reimbursement of medication was the main cost driver ob-
served in our analysis. Drugs made up more than 93% to PR, CR or SD, 91% to PD and
88% to death of the total cost per patient respectively.
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OBJECTIVES: To characterize resource utilization and associated costs of patients
receiving systemic therapy outside of a clinical trial for unresectable stage III and IV
metastatic melanoma in Brazilian Healthcare System, and to compare results
across the public and private health systems.METHODS:A retrospective study was
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